ATE234812T1 - Integrin antagonisten - Google Patents
Integrin antagonistenInfo
- Publication number
- ATE234812T1 ATE234812T1 AT97952325T AT97952325T ATE234812T1 AT E234812 T1 ATE234812 T1 AT E234812T1 AT 97952325 T AT97952325 T AT 97952325T AT 97952325 T AT97952325 T AT 97952325T AT E234812 T1 ATE234812 T1 AT E234812T1
- Authority
- AT
- Austria
- Prior art keywords
- integrin antagonists
- compounds
- restenotic
- disorders
- vitro
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76211796A | 1996-12-09 | 1996-12-09 | |
| PCT/US1997/022495 WO1998025892A1 (en) | 1996-12-09 | 1997-12-08 | Integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE234812T1 true ATE234812T1 (de) | 2003-04-15 |
Family
ID=25064189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97952325T ATE234812T1 (de) | 1996-12-09 | 1997-12-08 | Integrin antagonisten |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0963370B1 (de) |
| JP (1) | JP2001506632A (de) |
| AT (1) | ATE234812T1 (de) |
| AU (1) | AU5596298A (de) |
| CA (1) | CA2272090A1 (de) |
| DE (1) | DE69720062D1 (de) |
| WO (1) | WO1998025892A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0946164A4 (de) * | 1996-10-30 | 2000-08-23 | Merck & Co Inc | Integrin antagonisten |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| WO2001010844A1 (fr) | 1999-08-05 | 2001-02-15 | Meiji Seika Kaisha, Ltd. | DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE |
| CZ20011872A3 (cs) | 1999-09-29 | 2002-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| DE60130910T2 (de) | 2000-04-17 | 2008-07-10 | Ucb Pharma, S.A. | Enamin-derivate als zell-adhäsionsmoleküle |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6740654B2 (en) | 2000-07-07 | 2004-05-25 | Celltech R & D Limited | Squaric acid derivatives |
| AU2001275724A1 (en) | 2000-08-02 | 2002-02-13 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| US6500630B2 (en) | 2001-01-12 | 2002-12-31 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
| EP1389205B1 (de) | 2001-04-09 | 2005-12-21 | Ortho-McNeil Pharmaceutical Research Inc. | Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen |
| JP4660067B2 (ja) | 2001-04-24 | 2011-03-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血管新生剤とＴＮＦαとを用いる組合せ療法 |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| BRPI0706540A2 (pt) | 2006-01-18 | 2011-03-29 | Merck Patent Gmbh | terapia especìfica usando ligantes de integrina para tratar cáncer |
| EP2441464B1 (de) | 2007-01-18 | 2014-04-09 | Merck Patent GmbH | Integrin-liganden zur verwendung in der behandlung von darmkrebs |
| KR101072899B1 (ko) * | 2008-01-21 | 2011-10-17 | 주식회사 파나진 | 아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용 |
| CN102448497A (zh) | 2009-05-25 | 2012-05-09 | 默克专利有限公司 | 在癌症治疗中的西仑吉肽的持续给药 |
| ES2864079T3 (es) | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08504194A (ja) * | 1992-12-01 | 1996-05-07 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプターアンタゴニスト |
| ATE308981T1 (de) * | 1995-08-14 | 2005-11-15 | Scripps Research Inst | Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese |
| DE19548709A1 (de) * | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
| DE69710319T2 (de) * | 1996-03-29 | 2002-08-14 | G.D. SEARLE & CO., CHICAGO | Para-substituierte phenylpropansäure derivate als integrin-antagonisten |
-
1997
- 1997-12-08 WO PCT/US1997/022495 patent/WO1998025892A1/en not_active Ceased
- 1997-12-08 AT AT97952325T patent/ATE234812T1/de not_active IP Right Cessation
- 1997-12-08 DE DE69720062T patent/DE69720062D1/de not_active Expired - Lifetime
- 1997-12-08 AU AU55962/98A patent/AU5596298A/en not_active Abandoned
- 1997-12-08 CA CA002272090A patent/CA2272090A1/en not_active Abandoned
- 1997-12-08 JP JP52687298A patent/JP2001506632A/ja active Pending
- 1997-12-08 EP EP97952325A patent/EP0963370B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU5596298A (en) | 1998-07-03 |
| EP0963370A1 (de) | 1999-12-15 |
| JP2001506632A (ja) | 2001-05-22 |
| EP0963370B1 (de) | 2003-03-19 |
| WO1998025892A1 (en) | 1998-06-18 |
| CA2272090A1 (en) | 1998-06-18 |
| DE69720062D1 (de) | 2003-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE234812T1 (de) | Integrin antagonisten | |
| WO2000071493A3 (en) | INHIBITORS OF FACTOR Xa | |
| TR199801255T2 (xx) | Vitronektin resept�r antagonistleri. | |
| FI962350A0 (fi) | BPM-12, BMP-13 sekä niiden jännettä indusoivat koostumukset | |
| BG64475B1 (bg) | Ципразидонови соли | |
| CY1112458T1 (el) | Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου | |
| TR200100754T2 (tr) | Glausomanın tedavi edilmesi için serotonerjik 5HT2. | |
| FR2773075B1 (fr) | Utilisation d'activateurs de ppar-gamma en dermatologie | |
| CO4910133A1 (es) | Antagonistas de 5-h[1f] | |
| BR9814040A (pt) | Agudo no pulmão com fibrose com antagonistas de avb6 | |
| DK1077941T3 (da) | Forbindelser med væksthormonfrigörende egenskaber | |
| WO1996040743A3 (en) | Inhibitors of factor xa | |
| DE60041418D1 (de) | Zusammensetzung für hydrogele, hydrogel und dessen verwendung | |
| AU1667500A (en) | N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists | |
| MX9101958A (es) | Inhibidores de acat de urea de aminosulfonilo | |
| FI971127A7 (fi) | 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollagee nin kypsymis- ja rakentumishäiriöiden hoitamiseen | |
| TR200001102T2 (tr) | İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları. | |
| BR0014294A (pt) | Quinazolinonas | |
| DE68921127D1 (de) | Schienenwagen und dessen Konstruktionsverfahren. | |
| PT929299E (pt) | 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos | |
| NO20002408D0 (no) | 5-HT1F antagonister | |
| DK1100824T3 (da) | Forbindelser med væksthormonfrigivende egenskaber | |
| WO2002006280A3 (en) | INHIBITORS OF FACTOR Xa | |
| IT1304846B1 (it) | Composizione ecologica autoestinguente per la realizzazione di formeplastiche, stucchi, pannelli e simili. | |
| BR0015424A (pt) | Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |